Loading clinical trials...
Loading clinical trials...
A Single-Arm, Open-Label, Phase I Trial to Assess the Safety of Genetically Engineered Autologous T Cells Targeting the Cell Surface Antigen Mesothelin With Cell-Intrinsic Checkpoint Inhibition in Patients With Mesothelioma
Conditions
Interventions
cyclophosphamide
CAR T cells
Locations
1
United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States
Start Date
September 30, 2020
Primary Completion Date
September 30, 2026
Completion Date
September 30, 2026
Last Updated
July 25, 2025
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions